{"filing":{"accession_number":"0001493152-26-034938","cik":"0002029039","ticker":"NSRX","company_name":"Nasus Pharma Ltd","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2029039/000149315226034938/form6-k.htm"},"events":[{"id":20940,"run_id":18861,"accession_number":"0001493152-26-034938","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"The exhibit announces the appointment of Brendan P. O'Grady as Chief Executive Officer of Nasus Pharma, effective July 27, 2026, succeeding Dan Teleman. This is a material executive appointment of a named officer to a principal leadership role. The disclosure includes O'Grady's extensive qualifications (35 years of pharma experience, prior CEO roles at Teva USA and Assertio Holdings) and the Board's rationale for the appointment, making it a clear and material governance event affecting the registrant's leadership.","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":[{"id":20450,"accession_number":"0001493152-26-034938","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"The exhibit announces the appointment of Brendan P. O'Grady as Chief Executive Officer of Nasus Pharma, effective July 27, 2026, succeeding Dan Teleman. This is a material executive appointment of a named officer to a principal leadership role. The disclosure includes O'Grady's extensive qualifications (35 years of pharma experience, prior CEO roles at Teva USA and Assertio Holdings) and the Board's rationale for the appointment, making it a clear and material governance event affecting the registrant's leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:35:38.082423+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20450,"accession_number":"0001493152-26-034938","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"The exhibit announces the appointment of Brendan P. O'Grady as Chief Executive Officer of Nasus Pharma, effective July 27, 2026, succeeding Dan Teleman. This is a material executive appointment of a named officer to a principal leadership role. The disclosure includes O'Grady's extensive qualifications (35 years of pharma experience, prior CEO roles at Teva USA and Assertio Holdings) and the Board's rationale for the appointment, making it a clear and material governance event affecting the registrant's leadership.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:35:38.082423+00:00","company_name":"Nasus Pharma Ltd","ticker":"NSRX","filing_date":"2026-07-28"}]}